Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 7/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7557024 | 0.83 | LIPE (1.00) | LIPEMEN1KMT2A | |
| SCHEMBL7551658 | 0.80 | LIPE (0.69) | LIPEHPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL7551383 | 0.78 | LIPE (0.73) | LIPEMEN1KMT2ATP53MAPT | |
| SCHEMBL7552689 | 0.78 | LIPE (0.77) | LIPEHPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7549063 | 0.78 | LIPE (0.73) | LIPEMEN1KMT2ALMNAMAPT | |
| SCHEMBL7552676 | 0.78 | LIPE (1.00) | LIPESMN1; SMN2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL7549708 | 0.77 | LIPE (1.00) | LIPEHPGDSMN1; SMN2TP53 | |
| SCHEMBL14907228 | 0.73 | LIPE (0.66) | LIPESMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL7549145 | 0.73 | LIPE (1.00) | LIPEHPGDSMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL7550918 | 0.73 | LIPE (0.81) | LIPEHPGDSMN1; SMN2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001087843-A1 | COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED | NOVO NORDISK A/S (DK) | 2001-11-22 | — | — | WO | claimed |
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | NOVO NORDISK A/S (DK) | 2002-06-27 | — | — | US | disclosed |
| WO-2001087843-A1 | COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED | NOVO NORDISK A/S (DK) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | FABP1, FFAR2, FFAR1 | LIPE 109/4885HPGD 881/4885SMN1; SMN2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.